UBE2I Antibody

中文名稱：

UBE2I兔多克隆抗體
貨號：

CSB-PA00474A0Rb
規格：

￥440
圖片：
Western blot
All lanes: UBE2I antibody at 2µg/ml
Lane 1: 293T whole cell lysate
Lane 2: EC109 whole cell lysate
Secondary
Goat polyclonal to rabbit IgG at 1/15000 dilution
Predicted band size: 19 kDa
Observed band size: 19 kDa

Immunohistochemistry of paraffin-embedded human lung tissue using CSB-PA00474A0Rb at dilution of 1:100
其他：

產品詳情
產品評價
相關產品
靶點詳情

產品詳情

產品名稱：

Rabbit anti-Homo sapiens (Human) UBE2I Polyclonal antibody
Uniprot No.：

P63279
基因名：

UBE2I
別名：

C358B7.1 antibody; p18 antibody; SUMO 1 protein ligase antibody; SUMO conjugating enzyme UBC9 antibody; SUMO-conjugating enzyme UBC9 antibody; SUMO-protein ligase antibody; SUMO1 protein ligase antibody; UBC9 antibody; UBC9_HUMAN antibody; UBCE9 antibody; Ube2i antibody; Ubiquitin carrier protein 9 antibody; Ubiquitin carrier protein antibody; Ubiquitin carrier protein I antibody; Ubiquitin conjugating enzyme 9 antibody; Ubiquitin conjugating enzyme E2I (homologous to yeast UBC9) antibody; Ubiquitin conjugating enzyme E2I (UBC9 homolog; yeast) antibody; Ubiquitin conjugating enzyme UbcE2A antibody; Ubiquitin like protein SUMO 1 conjugating enzyme antibody; Ubiquitin protein ligase E2I antibody; Ubiquitin-conjugating enzyme E2 I antibody; Ubiquitin-protein ligase I antibody
宿主：

Rabbit
反應種屬：

Human
免疫原：

Recombinant Human SUMO-conjugating enzyme UBC9 protein (1-157AA)
免疫原種屬：

Homo sapiens (Human)

標記方式：

Non-conjugated

本頁面中的產品，UBE2I Antibody (CSB-PA00474A0Rb)，的標記方式是Non-conjugated。對于UBE2I Antibody，我們還提供其他標記。見下表：

標記方式	貨號	產品名稱	應用
HRP	CSB-PA00474B0Rb	UBE2I Antibody, HRP conjugated	ELISA
FITC	CSB-PA00474C0Rb	UBE2I Antibody, FITC conjugated
Biotin	CSB-PA00474D0Rb	UBE2I Antibody, Biotin conjugated	ELISA

克隆類型：

Polyclonal
抗體亞型：

IgG
純化方式：

>95%, Protein G purified
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, PH 7.4
產品提供形式：

Liquid
應用范圍：

ELISA, WB, IHC

推薦稀釋比：

Application	Recommended Dilution
WB	1:500-1:5000
IHC	1:20-1:200

Protocols：

ELISA Protocol
Western Blotting (WB) Protocol
Immunohistochemistry (IHC) Protocol
儲存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產品評價

靶點詳情

功能：

Accepts the ubiquitin-like proteins SUMO1, SUMO2, SUMO3, SUMO4 and SUMO1P1/SUMO5 from the UBLE1A-UBLE1B E1 complex and catalyzes their covalent attachment to other proteins with the help of an E3 ligase such as RANBP2, CBX4 and ZNF451. Can catalyze the formation of poly-SUMO chains. Necessary for sumoylation of FOXL2 and KAT5. Essential for nuclear architecture and chromosome segregation. Sumoylates p53/TP53 at 'Lys-386'. Mediates sumoylation of ERCC6 which is essential for its transcription-coupled nucleotide excision repair activity.
基因功能參考文獻：
1. Study demonstrated overexpression of Ubc9 protein in osteosarcoma. Silencing Ubc9 in osteosarcoma cell lines induced decoupling of SUMO1 from Cx43, generating increased free Cx43 levels, which is important for reconstructing gap junction intercellular communication and recovering cellular functions. PMID: 29956745
2. Data show that the forkhead Box Protein P3 (FOXP3) response element at the -310 bp region, but not the -2182 bp region, is mainly required for ubiquitin conjugating enzyme 9 (UBC9) activation by FOXP3. PMID: 30011797
3. Study provides an insight into the role of the RNF4 to balance the role of SUMO signaling by directly targeting Ubc9 and SUMO E3 ligases. PMID: 29180619
4. The SUMO1/UBC9 axis may regulate Nox1mediated diabetic retinopathy by inhibiting reactive oxygen species generation and apoptosis. PMID: 29138839
5. our results indicate that down-regulation of UBC9 sensitizes cells to anticancer drugs, is possibly associated with the regulation of ERK1/2 and P38 activation and interacts with the intrinsic apoptosis pathway. PMID: 28572537
6. Ubc9 is an essential regulator of ADAP where it is required for TCR-induced membrane recruitment of the small GTPase Rap1 and its effector protein RapL and for activation of the small GTPase Rac1 in T cell adhesion. PMID: 29127148
7. NUSAP1 contributes to accurate chromosome segregation by acting as a co-factor for RanBP2-RanGAP1-UBC9 during cell division. PMID: 28900032
8. Listeriolysin O -induced down-regulation of Ubc9 is independent of Ubc9-SUMO interaction, however, it may involve phosphorylation signaling. PMID: 28911869
9. Sumoylation of PML with SUMO2 by UBC9/UBE2I can lead to formation of polymeric SUMO chains. Data suggest that coordination of growing poly-SUMO chain with "back side" binding site on UBC9/UBE2I appears to be required for SUMO chain elongation on PML. (PML = promyelocytic leukemia protein; SUMO2 = small ubiquitin-like modifier 2; UBC9/UBE2I = ubiquitin-conjugating enzyme UBC9/UBE2I) PMID: 28784659
10. The role of Transthyretin in the regulation of Ubc9 SUMOylation PMID: 27501389
11. These findings point to UBC9 and autophagy as novel hallmarks of human papillomavirus oncogenesis PMID: 28253371
12. These findings reveal that SUMO E1~E2 oxidation is an essential redox switch in oxidative stress. PMID: 27174643
13. the mRNA and protein expression of Ubc9 are regulated by the microRNA miRNA-30a (miR-30a) in human subcutaneous adipocytes. PMID: 27758866
14. miR-30e in VSMCs exerted an anti-atherosclerosis effect via inhibiting proliferation and migration, and promoting apoptosis of VSMCs. More specifically, it was demonstrated that miR-30e exhibited these effects on VSMCs partially through targeting Ube2i and downregulating the IkappaBalpha/NFkappaB signaling pathway. PMID: 28123167
15. Ubc9 plays different roles of action in antitumor agents in chemotherapy. The process requires bleomycin hydrolase and poly(ADP-ribose) polymerase-1. The results are beneficial to deeply understanding of Ubc9 functions and for precise prediction of chemotherapy outcomes in tumors. PMID: 27878232
16. Suggest a novel role of PCGF2 in arsenic trioxide-mediated degradation of PML-RARA that PCGF2 might act as a negative regulator of UBE2I via direct interaction. PMID: 27030546
17. Akt directly phosphorylates Ubc9 at Thr35 and phosphorylates SUMO1 at Thr76. Ubc9 phosphorylation at Thr35 promotes Ubc9 thioester bond formation and SUMO1 phosphorylation at Thr76 stabilizes the SUMO1 protein. PMID: 25867063
18. Characterization and Structural Insights into Selective E1-E2 Interactions in the Human and Plasmodium falciparum SUMO Conjugation Systems. PMID: 26697886
19. a high-throughput microscopy screen identified ubiquitin carrier protein 9 (Ubc9) as a negative regulator of energy storage in human sc adipocytes. Ubc9 depletion enhanced energy storage and induced the brown fat gene program in human sc adipocytes. PMID: 26192107
20. The authors show that ZNF451 is SUMO2 specific and that SUMO modification of ZNF451 may contribute to activity by providing a second molecule of SUMO that interacts with E2. PMID: 26524494
21. The RWD domain binds to a Ubc9 surface that also must interact with E1, E3, and SUMO. PMID: 25918163
22. These data show that NS5A is a target protein of small ubiquitin-like modifier (SUMO) and is SUMOylated at lysine residue 348 and silencing of UBC9 impaired hepatitis C virus replication. PMID: 24602294
23. SUMO E2 ligase Ubc9 has a critical role in oncogenesis driven by the Ras/Raf pathway PMID: 25805818
24. Ubc9 gene plays an important role in cell proliferation in epithelial ovarian cancer through PI3K/Akt signaling pathway. PMID: 23708104
25. Data indicate that protein tyrosine phosphatase 1B (PTP1B) association with calnexin is ubiquitin conjugating enzyme 9 (UBC9)-dependent. PMID: 25586181
26. N-terminal amino acid residues of Ubc9 are critical for Ubc9 nuclear enrichment and localization. PMID: 25637535
27. the Ran system and Ubc9 are functionally coupled to the structure of the nuclear lamina and reactive oxygen species production through feedback loops PMID: 24523287
28. Although E2 approximately SUMO-1 exhibits no specificity for product-bound TDG, the relatively high conjugation efficiency raises the possibility that E2-mediated sumoylation could stimulate product release in vivo. PMID: 24753249
29. The variability of the UBC9 gene can play a role in breast cancer occurrence. PMID: 23873416
30. UBC9 appears to play an important role in the tumor biology of Nigerian women. PMID: 24176171
31. miR-214 and its target gene UBC9 may contribute to the development and the clinical outcome of glioma PMID: 24277415
32. The proximal UBC9 promoter. PMID: 24086615
33. Study showed that ZHX1 is SUMOylated by Ubc9 with SUMO1 at the sites K159, K454, and K626 and that the SUMOylation of ZHX1 regulated the stability, ubiquitination and transcriptional activity of ZHX1. PMID: 23686912
34. This study provides further insight in the processing and packaging of the HIV-1 gp120 into mature HIV-1 virions. PMID: 23861967
35. We observed steady-state expression of SUMO-conjugated enzyme-UBC9 throughout normal gestation. Placental UBC9 levels were strikingly increased in severe pre-eclampsia patients. PMID: 23628505
36. These results suggest that the SUMOylation of DDB2 facilitates CPD repair. PMID: 23860269
37. we demonstrated that upregulation of Ubc9 expression promotes migration and invasion. Ubc9 likely plays an important role in cancer progression by promoting invasion and metastasis in lung cancer. PMID: 23381475
38. High UBC9 expression is associated with glioma. PMID: 23187003
39. From these observations, we concluded that UBC9 is a novel regulator of the mammalian ER stress response. PMID: 23470653
40. The E2 enzyme Ubc9 is an interaction partner of E1B-55K, providing a possible molecular explanation for SUMO-dependent modulation of cellular target proteins. PMID: 22614022
41. A previously undescribed SIRT1/Ubc9 regulatory axis in the modulation of protein sumoylation and the hypoxia response. PMID: 23395904
42. High Ubc9 expression correlates with poor response to chemotherapy and poor clinical prognosis in breast cancer. PMID: 21880185
43. Data show that the SAE2 subunit of the small ubiquitin-like modifier (SUMO) E1 is autoSUMOylated at residue Lys-236, and SUMOylation was catalyzed by Ubc9 at several additional Lys residues surrounding the catalytic Cys-173 of SAE2. PMID: 22403398
44. UBC9 protein expression is reduced in muscle from type 2 diabetic patients with severe insulin resistance. PMID: 22114711
45. There was no statistical association of UBE2I expression between human epithelial ovarian cancer tumor and normal tissues PMID: 21971700
46. Ubc9 and PIAS1 potentiated SF-1-mediated transactivation of human CYP17, CYP11A1, and CYP11B1 but not CYP11B2 promoters. PMID: 21467194
47. Binding of BRCA1 proteins to nuclear chaperone Ubc9 provides a novel mechanism for nuclear import and control of tumor growth. PMID: 21344391
48. The authors propose that LMP1, by interaction with Ubc9, modulates sumoylation processes, which regulate signal transduction pathways that affect phenotypic changes associated with oncogenesis. PMID: 21795333
49. The authors report that the high risk human papillomavirus E6 proteins reduce the intracellular quantity of the sole SUMO conjugation enzyme, Ubc9, concomitant with decreased host sumoylation. PMID: 21510985
50. Analysis of the dynamics of E2(Ubc9)-SUMO-Target(RanGAP1) in the absence and presence of E3(RanBP2) revealed that two different allosteric sites regulate the ligase activity. PMID: 21216249
顯示更多

收起更多
亞細胞定位：

Nucleus. Cytoplasm.
蛋白家族：

Ubiquitin-conjugating enzyme family
組織特異性：

Expressed in heart, skeletal muscle, pancreas, kidney, liver, lung, placenta and brain. Also expressed in testis and thymus.
數據庫鏈接：

HGNC: 12485

OMIM: 601661

KEGG: hsa:7329

STRING: 9606.ENSP00000324897

UniGene: Hs.302903

Most popular with customers

YWHAG Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
YWHAB Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, FC

Species Reactivity: Human, Mouse, Rat
XRCC5 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF

Species Reactivity: Human
XPNPEP1 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
XDH Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WT1 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human
WDR5 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human